Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

We recently compiled a list of the Jim Cramer Recently Discussed These 17 Stocks And Chinese Hackers. In this article, we are ...

We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...

The race is on for new drugs that suppress appetite, improve glucose regulation and can replace injections. But do they ...

Eli Lilly expects its experimental weight loss pill, orforglipron, to receive approval as early as next year, CEO David Ricks told Bloomberg Jan. 13, according to a Wall Street Journal report.

Eli Lilly (LLY) expects that its experimental weight loss pill will get approved as soon as early next year, CEO David Ricks said in an ...

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which dominate the weight loss drug market.

Ozempic, Wegovy or Mounjaro? The battle of the weight-loss injections - As drugs emerge as vital to the Government’s ...

A non-opioid painkiller from Vertex Pharmaceuticals could become a blockbuster, but questions remain on whether it will prove ...